19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace

 

 

 

 


powered by centersite dot net
Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
AHA News: For Kids, a Pandemic of Stress Could Have Long-Term Consequences6 Expert Tips for Defusing Kids' Quarantine MeltdownsFor Many Kids, Picky Eating Isn't Just a Phase, Study FindsSure-Fire Solutions for Managing Lockdown Temper TantrumsKeeping Kids Slim, Fit During Lockdown Isn't Easy: Here Are Some TipsCOVID-19 Antibodies May Tame Inflammatory Condition in Kids: StudyCould Certain Chemicals Trigger Celiac Disease?Italian Doctors Detail Cases of Inflammatory Condition in Kids With COVID-19AHA News: Is Your Child's Blood Pressure Something to Worry About?Zika Virus Tied to Profound Developmental DelaysCOVID-19 Still Rare in Kids, But Far From Harmless: StudyKids' ER Visits for Mental Health Problems Soared Over 10 YearsTo Prevent Injuries, Give Your Kids a Pass on Cutting the GrassFewer Kids in Cancer Trials, Which Might Not Be a Bad ThingLoving Family May Lower Future Depression Risk in KidsBest Ways to Help Kids Through the PandemicIn Rare Cases, COVID-19 May Be Causing Severe Heart Condition in KidsReplace That Old Carpet to Shield Your Kids From ToxinsCoronavirus Crisis Has Fewer Kids Getting Needed VaccinesAHA News: Traumatic Childhood Increases Lifelong Risk for Heart Disease, Early DeathFDA Bans Products That Help Kids Hide Vape Use From ParentsCalm Parenting Will Help Children Through Coronavirus PandemicStudy Confirms Safety, Effectiveness of Children's VaccinesUp to 50,000 U.S. Kids May Be Hospitalized With COVID-19 by Year's EndAre Immune-Compromised Kids at Greater Risk From COVID-19?All That Social Media Hasn't Hurt Kids' Social Skills, Study FindsKids of Mentally Ill Parents Have Higher Injury OddsSchool Closures Could Be Adding to Kids' WaistlinesU.S. Study Finds COVID-19 Seldom Severe in KidsWhy Your Kids' Playground Is Unsafe During COVID-19 PandemicSchool Closures Will Force Many U.S. Health Care Workers to Stay HomeGoing Easy on Yourself Is Key to Parenting Through the PandemicParents, Arm Your Kids Against COVID-19 With Good Hand-Washing HabitsToo Little Sleep Takes Toll on Kids' Mental Health: StudyU.S. Kids, Teens Eating Better But Nutrition Gaps PersistHow to Keep Housebound Kids Busy During a PandemicCalming Your Child's Coronavirus FearsAnother Study Finds COVID-19 Typically Mild for KidsSoap vs. Coronavirus: Best Hand-Washing Tips for You and Your KidsKids Get Mild COVID-19 Symptoms, But Chance of Transmission High: StudyWhen Chronic Pain Leads to Depression in KidsPost-Game Snacks May Undo Calorie-Burning Benefit of Kids' SportsPick Summer Camps Carefully When Your Kid Has Allergies, AsthmaKids Raised by Grandparents More Likely to Pile on Pounds: StudyKeep Your Kids Safe, Warm in Wintertime FunHow to Dispel Your Child's Fears About the New CoronavirusDiabetes Among U.S. Young, Especially Asians, Continues to ClimbMom-to-Be's Cosmetics Chemicals Could Lead to Heavier BabyMeds May Not Prevent Migraines in KidsAHA News: For Kids With Heart Defects, the Hospital Near Mom May Matter
Questions and AnswersVideosLinksBook Reviews
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Parenting

FDA Expands Cystic Fibrosis Treatment Approval to Children Ages 6 to 12


HealthDay News
Updated: Jun 24th 2019

new article illustration

MONDAY, June 24, 2019 (HealthDay News) -- The indication for a cystic fibrosis treatment, Symdeko (tezacaftor/ivacaftor) tablets, has been expanded to treat children ages 6 years and older with cystic fibrosis and certain genetic mutations, the U.S. Food and Drug Administration announced today.

Symdeko is approved to treat patients with two copies of the F508del mutation, the most common type of mutation, and patients who have at least one of the mutations in the CFTR gene that is responsive to the active ingredients in Symdeko. The FDA approved Symdeko last year for treatment in children ages 12 years and older with the same genetic mutations. Dosage in children ages 6 to 12 years weighing less than 30 kg is one tablet of 50 mg tezacaftor and 75 mg ivacaftor in the morning and one tablet of 75 mg ivacaftor approximately 12 hours later. In patients aged 12 years and older or who weigh 30 kg or more, dosage is one tablet containing 100 mg tezacaftor and 150 mg ivacaftor and a tablet containing 150 mg ivacaftor 12 hours later.

Symdeko's approval was based on three phase 3, double-blind, placebo-controlled trials that showed improvements in lung function and a reduction in exacerbations. The expanded indication approval to children ages 6 to 12 years was based on data from patients aged 12 years and older and additional support from data on patients aged 6 to 12 years. Symdeko's safety in children ages 6 to 12 years was demonstrated in a 24-week, open-label study of 70 cystic fibrosis patients aged 6 to 12 years.

Symdeko's labeling indicates that it should always be taken with food containing fat and should never be combined with certain antibiotics, seizure medications, St. John's wort, or food containing grapefruit or Seville oranges. The prescribing information includes warnings of elevated transaminases and the risk for cataracts in children taking Symdeko and warns against taking Symdeko simultaneously with CYP3A inducers. The most commonly reported side effects were headache, nausea, sinus congestion, and dizziness.

Approval was granted to Vertex Pharmaceuticals.

More Information